Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Autism

    Current Location

    Search
    Autism
    Show Map
    Map View
    Your Location

    Popular Searches

    By Condition

    Depression Clinical Trials

    Anxiety Clinical Trials

    Schizophrenia Clinical Trials

    ADHD Clinical Trials

    Bipolar Disorder Clinical Trials

    Multiple Sclerosis Clinical Trials

    Autism Clinical Trials

    Treatment Resistant Depression Clinical Trials

    Borderline Personality Disorder Clinical Trials

    Social Anxiety Disorder Clinical Trials

    Parkinson's Disease Clinical Trials

    Alzheimer's Disease Clinical Trials

    By Location

    Clinical Trials in California

    Clinical Trials in Florida

    Clinical Trials in Texas

    Clinical Trials in New York

    Clinical Trials in Ohio

    Clinical Trials in Illinois

    Clinical Trials in Pennsylvania

    Clinical Trials in Michigan

    Clinical Trials in North Carolina

    Clinical Trials in Massachusetts

    Clinical Trials in Missouri

    Clinical Trials in Minnesota

    Other People Viewed

    By Subject

    13 Autism Trials near Dallas, TX

    15 Autism Trials near Chicago, IL

    Top Autism Clinical Trials near Miami, FL

    Top Autism Clinical Trials near San Diego, CA

    Top Autism Clinical Trials near Long Beach, CA

    4 Autism Trials near Tampa, FL

    30 Autism Trials near Albuquerque, NM

    14 Autism Trials near Cincinnati, OH

    Top Fibroids Clinical Trials

    Top Sarcoidosis Clinical Trials

    Top Epilepsy Clinical Trials

    Top Hypoglycemia Clinical Trials

    By Trial

    Levoleucovorin Calcium for Autism

    Sulforaphane for Autism

    Specialized Employment Program for Autism

    Pregnenolone for Autism

    Sertraline + Cognitive Behavioural Therapy for Anxiety in Autism

    Bedtime Routine for Autism

    Propofol-Etomidate Admixtures for Anesthesia

    ASP4396 for Solid Tumors

    Mobile Health and Social Media Intervention for Cancer Survivors

    Driver Training for Reducing Car Accidents

    Whole Brain vs Stereotactic Radiation for Brain Cancer

    Selective Dorsal Rhizotomy for Cerebral Palsy

    Related Searches

    Top Diabetes-type-2 Clinical Trials

    Top Treatment for Ibrutinib Clinical Trials

    Top Treatment for Carfilzomib Clinical Trials

    Top Treatment for Apixaban Clinical Trials

    Top Nafld Clinical Trials

    Provider Training and Patient Education for HIV Prevention

    AGTC-501 for Retinitis Pigmentosa

    Stem Cell Addback for Leukemia

    Cupping for Stroke Rehabilitation

    Adoptive T Cell Therapy for Adenovirus Infections After Bone Marrow Transplant

    Top Clinical Trials near Dallas, TX

    Enema Flush Regimen for Constipation

    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      121 Autism Trials Near You

      Power is an online platform that helps thousands of Autism patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Stimulant Medications for ADHD in Autism Spectrum Disorder

      Columbus, Ohio
      This study is a pragmatic clinical trial examining the comparative effectiveness of two stimulant medications (methylphenidate and amphetamine) in the treatment of ADHD in children and adolescents with autism. Using a sequential, multiple assignment randomization trial (SMART) design the study will not only assess these two medications but also the role of an increasingly popular class of ADHD medication, the alpha-2 agonists. Findings from this study will help improve clinicians' approach to medication selection and reduce the repeated trials of multiple medications that are current standard care.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4
      Age:4 - 17

      Key Eligibility Criteria

      Disqualifiers:Unstable Medications, Others
      Must Not Be Taking:ADHD Medications

      500 Participants Needed

      ML-004 for Autism

      Columbus, Ohio
      This trial is testing the safety of a treatment called ML-004 in adolescents and adults with Autism Spectrum Disorder (ASD). The main goal is to ensure that the treatment does not cause any harmful side effects.
      No Placebo Group

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Phase 2
      Age:12 - 46

      Key Eligibility Criteria

      Disqualifiers:Rett Syndrome, Epilepsy, Hypertension, Others

      120 Participants Needed

      ML-004 for Autism Spectrum Disorder

      Columbus, Ohio
      This trial is testing a treatment called ML-004 to see if it can help improve social communication skills in adolescents and adults with Autism Spectrum Disorder (ASD). The study will involve about 150 participants to determine its effectiveness.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:12 - 45

      Key Eligibility Criteria

      Disqualifiers:Rett Syndrome, Epilepsy, Hypertension, Others

      150 Participants Needed

      AquOTic for Autism Spectrum Disorder

      Columbus, Ohio
      AquOTic is an evidence-based, occupational therapy-led intervention designed to enhance water competency and swim safety skills in children on the autism spectrum. The 10-week program consists of weekly 60-minute group sessions, each including six children paired in a 1:1 ratio with an interventionist. Sessions follow a structured routine involving six rotating stations, targeting various swim and safety skills, with the flexibility for individualized support by the interventionist. Overall, this study has 3 major aims. The first aim evaluates the effectiveness of the AquOTic intervention in improving water competency and swim skills, while comparing outcomes between two implementation models: professional student interventionists (occupational and physical therapy students) and trained community-based interventionists. A total of 108 autistic children will be enrolled and randomly assigned to one of three groups: (1) AquOTic with professional student interventionists, (2) AquOTic with community interventionists, or (3) a control group receiving no AquOTic intervention. The second aim explores the mediators and moderators of the intervention outcomes to assess fidelity and efficacy. The third aim identifies the cost and resources associated with AquOTic. A cost analysis will be conducted to evaluate the resources required for implementation and to inform the development of a scalable, cost-effective drowning prevention strategy for autistic populations.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Unphased
      Age:5 - 9

      Key Eligibility Criteria

      Disqualifiers:Swim Proficiency, Open Wounds, Allergy, Severe Motor Impairments, Others

      108 Participants Needed

      Suicide Prevention Interventions for Autism

      Columbus, Ohio
      This trial is testing two methods to prevent suicide in autistic youth aged 12-24. One method involves creating a personalized safety plan, while the other adds ongoing support through periodic check-ins. The safety plan helps individuals recognize warning signs and use coping strategies, and the check-ins provide continuous support.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:12 - 99

      Key Eligibility Criteria

      Disqualifiers:Acute Psychosis, Intoxication, Mania, Others

      1665 Participants Needed

      Cariprazine for Pediatric Schizophrenia

      West Chester, Ohio
      This trial is testing the safety and effectiveness of cariprazine in children and teens with schizophrenia, bipolar I disorder, or autism. The goal is to see if the medication is safe and beneficial for use in these young patients.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:5 - 17

      Key Eligibility Criteria

      Disqualifiers:Major Depressive, Schizoaffective, Intellectual Disability, Others

      310 Participants Needed

      Theta Burst Stimulation for Depression and Autism

      Cincinnati, Ohio
      Evaluate the efficacy of accelerated theta burst stimulation (aTBS) in reducing depressive symptoms in autism spectrum disorder (ASD)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:13 - 26

      Key Eligibility Criteria

      Disqualifiers:Substance Use Disorder, Epilepsy, Others
      Must Not Be Taking:Anticonvulsants, Barbiturates, Lithium, Benzodiazepines

      24 Participants Needed

      Alpha Auditory Entrainment for Fragile X Syndrome

      Cincinnati, Ohio
      Fragile X Syndrome (FXS) is a complex neurodevelopmental disorder caused by a mutation on the X chromosome. Scientists have investigated FXS extensively in both humans and animals. Thus far, phenotypic rescue in animal models has not resulted in treatment breakthroughs in humans, though some important discoveries have been made. Research has shown that individuals with FXS process sounds differently than those in the typical population, and they also show baseline differences in brain activity, including high gamma activity, increased theta activity, and decreased alpha activity. The investigators' central hypothesis is that these alterations in brain activity (specifically alpha and gamma activity) impair the brain's ability to process new information, thereby impeding cognitive functioning and increasing sensory sensitivity. The investigators propose that auditory entrainment, a technique that involves playing special sounds through headphones, will normalize brain activity in individuals with FXS and lead to increased cognitive function and decreased sensory hypersensitivity.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:5 - 10

      Key Eligibility Criteria

      Disqualifiers:Auditory Impairments, Visual Impairments, Substance Abuse, Others

      180 Participants Needed

      Lumateperone for Schizophrenia and Bipolar Disorder

      Cincinnati, Ohio
      This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia, bipolar disorder or autism spectrum disorder.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:5 - 17

      Key Eligibility Criteria

      Disqualifiers:Suicidal Risk, Catatonia, Psychotic Features, Others
      Must Be Taking:Psychostimulants

      500 Participants Needed

      Lumateperone for Irritability in Autism

      Cincinnati, Ohio
      This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients aged 5 to 17 years with a primary diagnosis of irritability associated with Autism Spectrum Disorder (ASD) based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Text Revision (DSM-5-TR) and confirmed by the Kiddie Schedule for Affective Disorders and Schizophrenia Present and Lifetime Version (K-SADS-PL).
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:5 - 17

      Key Eligibility Criteria

      Disqualifiers:Rett Syndrome, Fragile X, Others
      Must Be Taking:ADHD Medications

      174 Participants Needed

      Therapy Dogs + Behavioral Treatment for Autism

      Cincinnati, Ohio
      This trial is testing if having a dog in therapy sessions can help children with autism manage their emotions better. It targets kids aged 8 to 15 who struggle with emotional control. The idea is that dogs can make therapy more enjoyable and less stressful, aiding in emotional learning. Using dogs in therapy is a growing practice in autism therapy, often involving dogs to help improve emotional and behavioral outcomes.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:8 - 15

      Key Eligibility Criteria

      Disqualifiers:Canine Phobia/allergy, Animal Aggression, Recent Child Aggression, Major Neuropsychiatric Illness, Major Sensory Impairment, Others

      240 Participants Needed

      Autism Doula Program for Autism

      Cincinnati, Ohio
      Background: Findings from a group level assessment with caregivers of Black children with autism revealed barriers to equitable care and services (e.g., a lack of cultural representation among their child's care team, caregiver stress, stigma, and uncertainty about services needed). The Autism Doula program was identified by the community to address the aforementioned barriers and provide culturally matched family navigation and social-emotional support while also acknowledging the unique experiences and values of caregivers of Black children with autism. Impact: The current project aims to assess the acceptability, feasibility, and preliminary effectiveness of the Autism Doula program and promote equitable care for Black children with autism and their families. Methods: Fifty-six Black families of children 18 months to five years of age who recently received a new diagnosis of autism spectrum disorder from CCHMC will be recruited to the current study. Twenty-six families will be randomly assigned to either the control group (i.e., care as usual including DDBP Family Navigation) or the intervention group (i.e., Autism Doula services). Feasibility and acceptability data will be gathered, including satisfaction of both groups, how many families approached agree to be in the study, how many sessions with the doula were successfully completed, and was the intervention content delivered as intended. Additionally, preliminary effectiveness will be evaluated by examining completion of recommended next steps, caregivers' perceived stress, and self-efficacy. Implications: Data from this project will provide evidence that the Autism Doula program is feasible, acceptable, and effective, ultimately demonstrating it as an equitable care approach for Black children with autism and their families. Future Directions: Findings from this pilot project will highlight the need for growth of the Autism Doula program to promote culturally competent care and health equity for Black children with autism and their families.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Non-Black Caregivers, Children Without Autism

      52 Participants Needed

      Social and Academic Interventions for Autism Spectrum Disorder

      Cincinnati, Ohio
      The goal of this study is to test how well two group interventions work for middle-school children with Autism Spectrum Disorder (ASD). One of the interventions focuses on teaching parents and adolescent skills to help improve their social functioning and the other focuses on teaching parents and adolescents skills to improve organization, planning, and study skills. Eligible participants will be randomly (like a coin flip) assigned to attend one of the two interventions.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:10 - 15

      Key Eligibility Criteria

      Disqualifiers:Home Schooled, Severe Psychopathology, Others

      224 Participants Needed

      Telehealth Programs for Autism

      Cincinnati, Ohio
      The current study seeks to compare outcomes of a telehealth intervention targeting daily living skills (Surviving and Thriving in the Real World - Telehealth, or STRW-T) intervention to a control group telehealth intervention targeting social skills (Program for the Education and Enrichment of Relational Skills- Telehealth, or PEERS-T). The key endpoint will be change in daily living skills on primary and secondary outcome measures at the end of treatment.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:15 - 21

      Key Eligibility Criteria

      Disqualifiers:Aggressive Behaviors, Mental Health Issues, Others

      192 Participants Needed

      Speech Perception for Autism and Fragile X Syndrome

      Cincinnati, Ohio
      The goal of this study is to identify which brain regions are active during speech-in-noise perception, as well as how those regions interact. The investigators are studying brain activation during speech-in-noise in autism and controls as well as individuals with Fragile X Syndrome. The main question\[s\] it aims to answer are: 1) How does the brain's response to background noise affect a person's ability to understand speech? 2) Can visual cues improve hearing in background noise? Participants will complete the following: * hearing tests * cognitive and behavioral measures * questionnaires about their symptoms * both passive and active hearing tasks while brain activity is recorded with a neuroimaging cap Results will be compared between individuals with autism with and without Fragile X Syndrome as well as individuals without autism.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:15 - 35

      Key Eligibility Criteria

      Disqualifiers:Hearing Loss, Uncorrected Vision, Others
      Must Not Be Taking:EEG-affecting Medications

      60 Participants Needed

      Regulating Together for Autism

      Cincinnati, Ohio
      This trial tests a program called Regulating Together, which helps children with autism manage their emotions. It targets kids aged 8-12 who struggle with emotional regulation. The program teaches them to recognize and control their feelings.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:8 - 12

      Key Eligibility Criteria

      Disqualifiers:Major Neuropsychiatric Illness, Sensory Impairment, Others

      144 Participants Needed

      Mobile Early Social Interaction Coaching for Toddler Autism

      Cincinnati, Ohio
      The goal of this collaborative R01 is to demonstrate the therapeutic value and community-wide implementability of an early intervention (EI) platform for toddlers with autism spectrum disorder (ASD) that is completely virtual, from recruitment through intervention. This platform-Early Social Interaction Mobile Coaching (ESI-MC) deploys individual telehealth sessions with coaching and feedback to help families embed intervention in everyday activities. Specifically, the investigators will conduct an effectiveness trial of ESI-MC to address the important question of whether starting evidence-based intervention earlier leads to better outcomes than starting later. The investigators will address this question by using a modified stepped wedge design and blended implementation research to analyze data obtained with ESI-MC start at 18, 24, or 30 months. The investigators will diagnostically ascertain 240 children from a pool of 360 18-month-olds with early signs of autism, 30 in each of 8 US regions (Central and SW Florida; Atlanta, GA; suburbs of Philadelphia, PA; New York City, NY; Cincinnati, OH; Chicago, IL; Seattle, WA; and Los Angeles, CA). Research participants will be recruited using a new virtual platform-My Baby Navigator-linking a new surveillance and screening tool, an app to upload video-recorded home observations and telehealth intervention sessions, and a package of educational resources. The 240 children will be randomly assigned to one of three ESI-MC timing groups. ESI-MC will be delivered by community-based early intervention providers (EIPs) currently working within the the early intervention system in the recruitment regions. The investigators will measure child active engagement and social communication change every 6 months as the primary outcome variables. Outcome measures of developmental level, autism symptoms, and adaptive behavior will be examined to measure differential treatment effects. Maximizing the use of mobile technology, ESI-MC offers the prospect of a community-viable, scalable and sustainable treatment to improve EI services for toddlers with ASD, particularly among minority and low-resource communities.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:15 - 20

      Key Eligibility Criteria

      Disqualifiers:No Autism, Motor Impairments, Others

      240 Participants Needed

      Pimavanserin for Autism Spectrum Disorder

      Cincinnati, Ohio
      This trial is testing pimavanserin, a medication that may help reduce irritability in children and teenagers with autism. The study focuses on kids aged 5 to 17 who have this symptom. Pimavanserin works by balancing brain chemicals to help them feel calmer. The goal is to see if the medication is safe and effective over time.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Age:5 - 18

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      209 Participants Needed

      Medical Cannabis for Chronic Pain

      Sandusky, Ohio
      This trial will investigate if medical cannabis can effectively reduce pain and improve quality of life for patients with chronic conditions. The study will gather data through an online questionnaire about patients' use of cannabis and its effects. Medical cannabis interacts with the body's natural system to help manage pain and other symptoms. Medical cannabis has been increasingly studied and used as an alternative treatment for managing chronic pain, with numerous studies supporting its potential benefits.
      Stay on current meds
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:7+

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Breastfeeding, Suicidality, Psychosis, Others

      200000 Participants Needed

      Lumateperone for Autism

      Avon Lake, Ohio
      This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients aged 5 to 17 years with a primary diagnosis of irritability associated with Autism Spectrum Disorder (ASD) based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Text Revision (DSM-5-TR) and confirmed by the Kiddie Schedule for Affective Disorders and Schizophrenia Present and Lifetime Version (K-SADS-PL).
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:5 - 17

      Key Eligibility Criteria

      Disqualifiers:Rett Syndrome, Fragile X, Suicidal Risk, Others
      Must Be Taking:ADHD Medications

      174 Participants Needed

      Why Other Patients Applied

      "I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

      AG
      Paralysis PatientAge: 50

      "I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

      FF
      ADHD PatientAge: 31

      "I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

      ID
      Pancreatic Cancer PatientAge: 40

      "As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

      IZ
      Healthy Volunteer PatientAge: 38

      "I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

      WR
      Obesity PatientAge: 58
      Match to a Autism Trial

      CM-AT for Autism

      Cleveland, Ohio
      This trial is testing a special enzyme powder called CM-AT to help children with autism digest protein better.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:3 - 17

      Key Eligibility Criteria

      Disqualifiers:Seizures, Severe Trauma, Systemic Disease, Others
      Must Not Be Taking:Stimulants, Non-stimulants, ADHD Meds

      405 Participants Needed

      CAST for Autism Spectrum Disorder

      Muncie, Indiana
      Purpose: The purpose of this project is to develop and test the COMPASS \[Collaborative Model for Competence and Success\] Across Settings (CAST) intervention to enhance the goal setting and attainment skills of autistic youth. Despite federal education law mandating transition services as part of the Individualized Education Program (IEP) for ensuring good outcomes for students with disabilities, current educational practices have been unable to demonstrate that autistic students experience positive postsecondary outcomes. There are existing, evidence-based interventions aimed at supporting positive outcomes for these students. However, these interventions have not systematically provided coaching support to the caregivers, students, and employment specialists. To address these issues, CAST will integrate three evidence-based interventions for supporting student transitions while providing this critical coaching support. By doing so, CAST aims to align the priorities and goals of interventions across home, school, and community settings to better support positive postsecondary outcomes for autistic students.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:16 - 99

      Key Eligibility Criteria

      Disqualifiers:Moving, Job Change, Others

      297 Participants Needed

      Sleep Intervention for Autism Spectrum Disorder

      Cleveland, Ohio
      As many as 78% of children with autism spectrum disorder (ASD) have significant sleep disturbance compared to 20% of children without ASD. In children with ASD, shorter sleep duration and lower sleep efficiency, are associated with disruptive behavior, anxiety, and increased parental stress. Therefore, multiple sleep dimensions (B-SATED: behaviors, satisfaction, alertness, timing, efficiency, duration) are appropriate therapeutic targets to improve daytime behavioral functioning and other psychosocial outcomes. The primary objective is to evaluate the implementation of a modification of a behavioral sleep and circadian intervention to improve multiple sleep dimension in school-age children with ASD. To accomplish this objective, a 12-week, randomized pilot study will be conducted to assess the feasibility, acceptability, and preliminary efficacy of a modified behavioral sleep and circadian intervention with up to 50 school-age children with ASD, to determine whether the intervention improves multiple dimensions of sleep (B-SATED: behaviors, satisfaction, alertness, timing, efficiency, duration), daytime behavior, quality of life, parental stress, and parental self-efficacy. This modified intervention is guided by the Pediatric Sleep Health Framework that encourages improvement in six pediatric sleep dimensions (B-SATED): sleep behaviors; parents' satisfaction with child sleep; daytime alertness/sleepiness; appropriate timing of sleep within the 24-hour day; sleep efficiency, i.e., ease of falling and staying asleep; and sleep duration. The Sadeh and Anders Sleep-Wake Regulation Model was used to propose linkages between outcomes. The investigators hypothesize that parents implementing the modified intervention will improve the primary outcome (clinician- and parent-ratings of child sleep) and secondary child (sleep dimensions, daytime behavior, quality of life) and parent outcomes (stress and self-efficacy).
      No Placebo Group

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Unphased
      Age:6 - 12

      Key Eligibility Criteria

      Disqualifiers:Epilepsy, Nocturnal Seizures, Moderate OSA, Others

      50 Participants Needed

      Virtual Interview Training for Autism

      Lincoln Park, Michigan
      The purpose of the study is to see if an internet job interview training program can help people that have autism improve interview skills and access to jobs. Participants will be randomized to use Virtual Interview Training (VIT) or continue services as usual (active control group).
      No Placebo Group

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Unphased
      Age:16 - 26

      Key Eligibility Criteria

      Disqualifiers:Not In Transition Services

      200 Participants Needed

      Cognitive Enhancement Therapy for Autism

      Pittsburgh, Pennsylvania
      This trial will test two therapies for adults with autism. One therapy aims to improve thinking and planning through mental exercises. The other provides support to help manage emotions and social skills. The study focuses on adults because there are few treatments available for them.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Age:16 - 45

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      86 Participants Needed

      Emotion Regulation Therapies for Autism

      Pittsburgh, Pennsylvania
      Too few clinicians are able and willing to help autistic patients. A recent review identified challenges to mental health service delivery in autism, including a lack of interventions designed for community implementation and limited workforce capacity. It has been argued that improving impairment in emotion regulation has the potential to improve a range of mental health difficulties in autistic people. In this clinical trial, the investigators are comparing two evidence-based interventions for emotion regulation, to determine if one created specifically for autistic people is clinically superior. The interventions will be implemented in the community, through partnering agencies.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:10 - 30

      Key Eligibility Criteria

      Disqualifiers:Acute Psychosis, Suicide Threat, Intoxication, Mania

      470 Participants Needed

      Online Work Chat Program for Autism

      Ann Arbor, Michigan
      This study is aiming to see if it is feasible for the intervention Work Chat to be delivered in a completely online setting to adults with autism spectrum disorder.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      90 Participants Needed

      Eye Tracking for Autism Detection

      Indianapolis, Indiana
      The study will use a non-invasive remote eye-tracking system (Eyelink Portable Duo) to acquire a short series of eye-tracking measures.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:12 - 48

      Key Eligibility Criteria

      Disqualifiers:Age, Language, Others

      100 Participants Needed

      Bedtime Routine for Autism

      Pittsburgh, Pennsylvania
      The goal of this pilot intervention study is to examine the feasibility and acceptability of a novel bedtime manipulation protocol called "The Power Down" for autistic youth, ages 6-10. The main questions it aims to answer are: 1. Is the Power Down feasible for caregivers to do each night? 2. Do the families find the Power Down an acceptable intervention to address their child's difficulties settling down to fall asleep?
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:6 - 10

      Key Eligibility Criteria

      Disqualifiers:Non-English Speakers, Trauma History, Others

      10 Participants Needed

      Reinforcement Strategies for Intellectual Disabilities

      Rochester Hills, Michigan
      This study is designed to better understand how certain features of reinforcement affect learning and motivation in individuals with intellectual and developmental disabilities (IDD). Participants will take part in a series of structured teaching sessions that involve simple tasks and reward-based feedback. By changing the timing and amount of rewards, we aim to learn how these factors influence the ability to acquire and maintain new skills. This information may help improve behavioral interventions for individuals with IDD in the future. The study does not involve medications or procedures intended to change participants' health status.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:6 - 17

      Key Eligibility Criteria

      Disqualifiers:Severe Sensory/motor Impairments, Others

      30 Participants Needed

      12345

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do Autism clinical trials pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Autism clinical trials work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Autism trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Autism is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Autism medical study?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Autism clinical trials?

      Most recently, we added Caregiver Interventions for Autism, Community Engagement for Autism and SDARI Program for Autism to the Power online platform.

      Is there still a spectrum for autism?

      Yes—medical guidelines still call it Autism Spectrum Disorder, but experts no longer picture that spectrum as a single line from “mild” to “severe.” Instead, it’s more like a sound-mixing board with many sliders: social communication, repetitive behaviors, sensory sensitivity, thinking style, and support needs can each sit at different points, creating a unique profile for every autistic person. Clinicians note these differences by assigning support levels (1-3) in each domain so interventions can be tailored rather than ranked.

      What is the biggest symptom of autism?

      There isn’t one “biggest” symptom of autism; doctors look for a pattern that includes BOTH social-communication differences (like trouble reading body language or carrying on back-and-forth conversation) and restricted, repetitive behaviours or intense interests/sensory sensitivities (such as needing strict routines or reacting strongly to noises). Which of these stands out most varies from person to person, so if you notice a persistent mix of them, the next step is to talk with your GP or a psychologist for a formal autism assessment and tailored support.

      Can maternal stress cause autism?

      Normal day-to-day worries during pregnancy have not been proven to cause autism. Large studies show that only very severe or long-lasting stress (such as the death of a close relative or a natural disaster) is linked to a small rise in risk—about 2 % to roughly 3 %—and even that link may partly reflect other genetic or environmental factors. Taking steps to manage high stress is good for overall maternal and baby health, but parents should not blame themselves or everyday stressors if a child is later diagnosed with autism.

      What is the life expectancy of someone with autism?

      Large registry studies (e.g., Sweden 2016, Denmark 2022) find that autistic people, on average, die 15–20 years earlier than non-autistic peers, with a median age of death around the mid-50s; the figure is lower (≈ 40s) when someone also has intellectual disability or uncontrolled epilepsy and higher (late 50s or beyond) when those conditions are absent. The gap is driven less by autism itself than by treatable or preventable issues—seizures, heart disease, accidents and suicide—so good medical follow-up, mental-health support and safety planning can help many autistic individuals live into typical older age.

      What is the best treatment for autism in the world?

      There is no one “best” treatment for every person with autism; the strongest evidence shows that progress comes from an individualized program that blends proven developmental-behavioral therapies (such as Applied Behavior Analysis or other naturalistic approaches) with speech-language and occupational therapy, parent coaching, and tailored educational supports. A multidisciplinary team adjusts this mix over time—and may add medication for anxiety, ADHD, or sleep problems—so the plan fits the person’s specific strengths, challenges, and goals, which is what international guidelines recommend for the best results.

      Is autism overdiagnosed?

      Rates of autism have risen sharply (e.g., from about 1 in 150 U.S. children in 2000 to 1 in 36 today), but most of that jump comes from broader definitions, better screening, and shifting other labels to “autism,” not from a sudden epidemic. Studies suggest roughly 1 in 10 people once given the label later lose it—evidence of some over-diagnosis—yet girls, adults, and many minority children are still frequently missed, so the real problem is uneven diagnosis rather than simply “too much” or “too little.” A careful, multidisciplinary assessment that also checks for ADHD, language disorders, anxiety, and other look-alike conditions is the best way to get an accurate answer for any individual.

      Who carries the autism gene?

      There is no single “autism gene.” Autism risk comes from a mix of many common genetic variants, rare mutations, and sometimes new (de-novo) changes that neither parent had; these can be inherited from either mother or father, while factors like higher paternal age and the female-protective effect can influence how that risk shows up. In short, either parent—or neither, if the change is new—can pass along genetic risk, so talking with a genetic counselor is the best way to understand a specific family’s situation.

      Which state has the highest rate of autism?

      In the latest CDC ADDM study, the surveillance area in California recorded the highest autism rate: roughly 4.5 % of 8-year-olds (about 45 children per 1,000). However, ADDM covers only parts of 11 states and other tracking systems use different methods, so rankings can change if you look at school records, insurance data, or adult estimates—meaning the numbers are useful for spotting trends, not declaring a single “most-autistic” state.

      Has anyone ever overcome autism?

      Autism is a lifelong neuro-developmental difference, so people don’t “overcome” it in the sense of being cured; instead, most continue to be autistic throughout life. With early, individualized supports and ongoing accommodations, many children and adults make major gains—some even lose the formal diagnosis—yet they often keep certain autistic traits and still benefit from understanding and acceptance. The practical aim is therefore not to erase autism but to build skills, reduce distress, and create environments where each autistic person can thrive.

      What was autism called in the 1980s?

      In the early-1980s diagnostic manual (DSM-III, 1980) autism was officially listed as “Infantile Autism,” and in the 1987 revision (DSM-III-R) the name was changed to “Autistic Disorder” under the larger category of “Pervasive Developmental Disorders.” Outside the U.S., doctors using the World Health Organization’s ICD-9 still called it “Childhood Autism.” In everyday practice, people might also have heard “Kanner’s autism” or “childhood psychosis,” but the two formal labels you would have seen on a medical chart during that decade were “Infantile Autism” at the start of the 1980s and “Autistic Disorder” by the end.